Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
There is also an ongoing cardiovascular outcomes trial of tirzepatide (SURPASS-CVOT) in individuals with type 2 diabetes and cardiovascular disease [91], which, if successful, will broaden the use of tirzepatide to those with manifest or increased risk for CVD, as is the case for GLP-1 receptor agonists [22]
However, GLP-1R agonists elicit nausea and vomiting 6,10 , and increase mean heart rate via directly stimulating sinoatrial node and enhancing sympathetic nervous system tone 10,11,12
Nature 458 , 780783
Starting both simultaneously significantly increases the risk of severe nausea, electrolyte imbalances, and dangerously low caloric intake
Lets break it down by thyroid condition: Primary Hypothyroidism Usually safe
People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use GLP-1 medications
